106 related articles for article (PubMed ID: 2144165)
1. Development and characterization of cisplatin-resistant human testicular and bladder tumour cell lines.
Walker MC; Povey S; Parrington JM; Riddle PN; Knuechel R; Masters JR
Eur J Cancer; 1990; 26(6):742-7. PubMed ID: 2144165
[TBL] [Abstract][Full Text] [Related]
2. Differential sensitivities of human testicular and bladder tumor cell lines to chemotherapeutic drugs.
Walker MC; Parris CN; Masters JR
J Natl Cancer Inst; 1987 Aug; 79(2):213-6. PubMed ID: 3474453
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of the unusual expression of cross resistance to cisplatin in a series of etoposide-selected resistant sublines of the SuSa testicular teratoma cell line.
Shellard SA; Hosking LK; Hill BT
Biochem Pharmacol; 1994 Mar; 47(5):775-9. PubMed ID: 8135853
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of collateral sensitivity or resistance to cisplatin in human bladder carcinoma cell lines pre-exposed in vitro to either X-irradiation or cisplatin.
Bedford P; Shellard SA; Walker MC; Whelan RD; Masters JR; Hill BT
Int J Cancer; 1987 Nov; 40(5):681-6. PubMed ID: 3679594
[TBL] [Abstract][Full Text] [Related]
5. Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation.
Hill BT; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Bedford P
Int J Radiat Oncol Biol Phys; 1990 Jul; 19(1):75-83. PubMed ID: 2380098
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells.
Kotoh S; Naito S; Yokomizo A; Kumazawa J; Asakuno K; Kohno K; Kuwano M
Cancer Res; 1994 Jun; 54(12):3248-52. PubMed ID: 8205547
[TBL] [Abstract][Full Text] [Related]
7. Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity.
Taverna P; Hansson J; Scanlon KJ; Hill BT
Carcinogenesis; 1994 Sep; 15(9):2053-6. PubMed ID: 7923602
[TBL] [Abstract][Full Text] [Related]
8. Decreased telomerase activity is not a reliable indicator of chemosensitivity in testicular cancer cell lines.
Cressey TR; Tilby MJ; Newell DR
Eur J Cancer; 2002 Mar; 38(4):586-93. PubMed ID: 11872354
[TBL] [Abstract][Full Text] [Related]
9. Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines.
Kelland LR; Kimbell R; Hardcastle A; Aherne GW; Jackman AL
Eur J Cancer; 1995 Jun; 31A(6):981-6. PubMed ID: 7646933
[TBL] [Abstract][Full Text] [Related]
10. Use of host cell reactivation of cisplatin-treated adenovirus 5 in human cell lines to detect repair of drug-treated DNA.
Maynard KR; Hosking LK; Hill BT
Chem Biol Interact; 1989; 71(4):353-65. PubMed ID: 2582540
[TBL] [Abstract][Full Text] [Related]
11. Accumulation of intracellular platinum is correlated with intrinsic cisplatin resistance in human bladder cancer cell lines.
Koga H; Kotoh S; Nakashima M; Yokomizo A; Tanaka M; Naito S
Int J Oncol; 2000 May; 16(5):1003-7. PubMed ID: 10762637
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothioneins.
Siegsmund MJ; Marx C; Seemann O; Schummer B; Steidler A; Toktomambetova L; Köhrmann KU; Rassweiler J; Alken P
Urol Res; 1999 Jun; 27(3):157-63. PubMed ID: 10422815
[TBL] [Abstract][Full Text] [Related]
13. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
Pera MF; Köberle B; Masters JR
Br J Cancer; 1995 May; 71(5):904-6. PubMed ID: 7734313
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-induced hemolysis.
Getaz EP; Beckley S; Fitzpatrick J; Dozier A
N Engl J Med; 1980 Feb; 302(6):334-5. PubMed ID: 7188625
[No Abstract] [Full Text] [Related]
15. Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors.
Higby DJ; Wallace HJ; Albert DJ; Holland JF
Cancer; 1974 May; 33(5):1219-5. PubMed ID: 4856724
[No Abstract] [Full Text] [Related]
16. Water as a tumoricidal agent in bladder cancer. In vitro studies in parental and resistant cell lines.
Solomon LZ; Birch BR; Cooper AJ
Eur Urol; 1998 Dec; 34(6):500-4. PubMed ID: 9831792
[TBL] [Abstract][Full Text] [Related]
17. Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines.
Bedford P; Fichtinger-Schepman AM; Shellard SA; Walker MC; Masters JR; Hill BT
Cancer Res; 1988 Jun; 48(11):3019-24. PubMed ID: 3365691
[TBL] [Abstract][Full Text] [Related]
18. Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines.
Hill BT; Shellard SA; Fichtinger-Schepman AM; Schmoll HJ; Harstrick A
Anticancer Drugs; 1994 Jun; 5(3):321-8. PubMed ID: 7919457
[TBL] [Abstract][Full Text] [Related]
19. Cross-resistance and combined cytotoxic effects of paclitaxel and cisplatin in bladder cancer cells.
Pu YS; Chen J; Huang CY; Guan JY; Lu SH; Hour TC
J Urol; 2001 Jun; 165(6 Pt 1):2082-5. PubMed ID: 11371932
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
Kelland LR; Mistry P; Abel G; Freidlos F; Loh SY; Roberts JJ; Harrap KR
Cancer Res; 1992 Apr; 52(7):1710-6. PubMed ID: 1312897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
